Characteristics of 10-year survivors of high-grade serous ovarian carcinoma

被引:79
作者
Dao, Fanny [1 ]
Schlappe, Brooke A. [1 ]
Tseng, Jill [1 ]
Lester, Jenny [2 ]
Nick, Alpa M. [3 ]
Lutgendorf, Susan K. [4 ,5 ]
McMeekin, Scott [6 ]
Coleman, Robert L. [3 ]
Moore, Kathleen N. [6 ]
Karlan, Beth Y. [2 ]
Sood, Anil K. [3 ]
Levine, Douglas A. [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Surg, Gynecol Serv, 1275 York Ave, New York, NY 10065 USA
[2] Cedars Sinai Med Ctr, Dept Obstet & Gynecol, Samuel Oschin Comprehens Canc Inst, Womens Canc Program, Los Angeles, CA 90048 USA
[3] Univ Texas MD Anderson Canc Ctr, Ctr RNA Interference & Noncoding RNA, Dept Gynecol Oncol, Dept Canc Biol, Dallas, TX USA
[4] Univ Iowa, Holden Comprehens Canc Ctr, Dept Psychol & Brain Sci, Dept Obstet & Gynecol, Iowa City, IA 52242 USA
[5] Univ Iowa, Holden Comprehens Canc Ctr, Dept Urol, Iowa City, IA 52242 USA
[6] Univ Oklahoma, Dept Obstet & Gynecol, Stephenson Oklahoma Canc Ctr, Div Gynecol Oncol, Oklahoma City, OK USA
关键词
Ovarian cancer; Long-term survival; Neoadjuvant chemotherapy; Surgical cytoreduction; Outcome; Survival; PROGNOSTIC-FACTORS; CANCER; MORTALITY; SURGERY; DISEASE;
D O I
10.1016/j.ygyno.2016.03.010
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. High-grade serous carcinoma (HGSC) generally presents at an advanced stage with poor long-term (LT) survival. Here we describe clinical features found in women surviving HGSC for ten or more years. Methods. A multi-center research consortium was established between five participating academic centers. Patient selection criteria included high-grade serous ovarian, fallopian tube, or peritoneal carcinoma with at least ten years of follow up. Non-serous, borderline tumors and low-grade serous subtypes were excluded. Results. The 203 identified LT ten-year survivors with HGSC were diagnosed at a median age of 57 years (range 37-84 years). The majority of patients had stage IIIC (72.4%) disease at presentation. Of those who underwent primary cytoreductive surgery, optimal cytoreduction was achieved in 143 (85.6%) patients. After a median follow up of 144 months, 88 (46.8%) patients did not develop recurrent disease after initial treatment. Unexpected findings from this survey of LT survivors includes 14% of patients having had suboptimal cytoreduction, 11% of patients having an initial platinum free interval of <12 months, and nearly 53% of patients having recurrent disease, yet still surviving more than ten years after diagnosis. Conclusions. LT survivors of HGSC of the ovary generally have favorable clinical features including optimal surgical cytoreduction and primary platinum sensitive disease. The majority of patients will develop recurrent disease, however many remained disease free for more than 10 years. Future work will compare the clinical features of this unusual cohort of LT survivors with the characteristics of HGSC patients having less favorable outcomes. (C) 2016 The Authors. Published by Elsevier Inc.
引用
收藏
页码:260 / 263
页数:4
相关论文
共 50 条
  • [31] Differences of chemoresistance assay between invasive micropapillary/low-grade serous ovarian carcinoma and high-grade serous ovarian carcinoma
    Santillan, A.
    Kim, Y. W.
    Zahurak, M. L.
    Gardner, G. J.
    Giuntoli, R. L., II
    Shih, I. M.
    Bristow, R. E.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2007, 17 (03) : 601 - 606
  • [32] Shortened Telomeres in Serous Tubal Intraepithelial Carcinoma: An Early Event in Ovarian High-grade Serous Carcinogenesis
    Kuhn, Elisabetta
    Meeker, Alan
    Wang, Tian-Li
    Sehdev, Ann Smith
    Kurman, Robert J.
    Shih, Ie-Ming
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2010, 34 (06) : 829 - 836
  • [33] Targeting DUSP Activity as a Treatment for High-Grade Serous Ovarian Carcinoma
    Sanders, Brooke E.
    Yamamoto, Tomomi M.
    McMellen, Alexandra
    Woodruff, Elizabeth R.
    Berning, Amber
    Post, Miriam D.
    Bitler, Benjamin G.
    MOLECULAR CANCER THERAPEUTICS, 2022, 21 (08) : 1285 - 1295
  • [34] Estrogen receptor expression and increased risk of lymphovascular space invasion in high-grade serous ovarian carcinoma
    Matsuo, Koji
    Sheridan, Todd B.
    Mabuchi, Seiji
    Yoshino, Kiyoshi
    Hasegawa, Kosei
    Studeman, Kimberley D.
    Im, Dwight D.
    Rosenshein, Neil B.
    Roman, Lynda D.
    Sood, Anil K.
    GYNECOLOGIC ONCOLOGY, 2014, 133 (03) : 473 - 479
  • [35] Schlafen 11 Assessment in High-Grade Serous Ovarian Carcinoma Phenotypic and Histological Distribution
    Ferraioli, Domenico
    Penuela, Leonardo
    Garuti, Anna
    Carrozzi, Chiara
    Olivier, Timothee
    Spina, Bruno
    Salvi, Sandra
    Ferrero, Simone
    Tille, Jean-Christophe
    Labidi-Galy, Sana Intidhar
    Cirmena, Gabriella
    Ballestero, Alberto
    Chopin, Nicolas
    Beurrier, Frederic
    Treilleux, Isabelle
    Ray-Coquard, Isabelle
    Zoppoli, Gabriele
    Vellone, Valerio Gaetano
    ANALYTICAL AND QUANTITATIVE CYTOPATHOLOGY AND HISTOPATHOLOGY, 2018, 40 (05): : 222 - 230
  • [36] High-grade ovarian serous carcinoma patients exhibit profound alterations in lipid metabolism
    Braicu, Elena Ioana
    Darb-Esfahani, Silvia
    Schmitt, Wolfgang D.
    Koistinen, Kaisa M.
    Heiskanen, Laura
    Poho, Paivi
    Budczies, Jan
    Kuhberg, Marc
    Dietel, Manfred
    Frezza, Christian
    Denkert, Carsten
    Sehouli, Jalid
    Hilvo, Mika
    ONCOTARGET, 2017, 8 (61) : 102912 - 102922
  • [37] Prognostic impact of neuroendocrine differentiation in high-grade serous ovarian carcinoma
    Taube, E. T.
    Denkert, C.
    Pietzner, K.
    Dietel, M.
    Sehouli, J.
    Darb-Esfahani, S.
    VIRCHOWS ARCHIV, 2015, 466 (03) : 333 - 342
  • [38] Identification of Ovarian High-Grade Serous Carcinoma with Mitochondrial Gene Variation
    Bosquet, Jesus Gonzalez
    Wagner, Vincent
    Polio, Andrew
    Linder, Katharine E.
    Bender, David P.
    Goodheart, Michael J.
    Schickling, Brandon M.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2025, 26 (03)
  • [39] A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma
    Han, Chanhee
    Bellone, Stefania
    Siegel, Eric R.
    Altwerger, Gary
    Menderes, Gulden
    Bonazzoli, Elena
    Egawa-Takata, Tomomi
    Pettinella, Francesca
    Bianchi, Anna
    Riccio, Francesco
    Zammataro, Luca
    Yadav, Ghanshyam
    Marto, Jarrod A.
    Penet, Marie-France
    Levine, Douglas A.
    Drapkin, Ronny
    Patel, Abhijit
    Litkouhi, Babak
    Ratner, Elena
    Silasi, Dan-Arin
    Huang, Gloria S.
    Azodi, Masoud
    Schwartz, Peter E.
    Santin, Alessandro D.
    GYNECOLOGIC ONCOLOGY, 2018, 149 (03) : 585 - 591
  • [40] Esophageal Infiltration by High-Grade Serous Ovarian Carcinoma: A Very Rare Case Report
    Carbo-Bague, Anna
    Ceron-Nasarre, Laura
    Valls-Masot, Laia
    Melendez-Munoz, Cristina
    Bujons-Buscarons, Elisabet
    Linan-Planas, Raquel
    Barretina-Ginesta, Maria Pilar
    CASE REPORTS IN ONCOLOGY, 2023, 16 (01): : 1436 - 1442